Dapagliflozin in patients with type 2 diabetes mellitus:a pooled analysis of safety data from phase IIb/III clinical trials

Volume: 20, Issue: 3, Pages: 620 - 628
Published: Mar 1, 2018
Abstract
Aim: To evaluate the safety and tolerability of dapagliflozin, a highly selective sodium-glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus (T2DM). Methods: Data were pooled from 13 placebo-controlled trials of up to 24weeks' duration (dapagliflozin, n=2360; placebo, n=2295). Larger placebo-/comparator-controlled pools of 21 (≤208weeks; dapagliflozin, n=5936; control, n=3403) and 30 trials (≥12weeks; dapagliflozin,...
Paper Details
Title
Dapagliflozin in patients with type 2 diabetes mellitus:a pooled analysis of safety data from phase IIb/III clinical trials
Published Date
Mar 1, 2018
Volume
20
Issue
3
Pages
620 - 628
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.